In its 2026 Q1 report, Harrow, Inc. disclosed ongoing pricing and reimbursement headwinds affecting revenue growth, while strategically expanding its FDA-approved ophthalmic portfolio and compounding capabilities. The company completed the full acquisition of Melt Pharmaceuticals late in 2025, gaining control of MELT-300, a late-stage sedation asset outside ophthalmology that could diversify future revenue streams. Harrow remains focused on scaling branded sales in the U.S. and Canada despite competitive and regulatory pressures prevalent in the ophthalmic pharmaceuticals sector.